全球Warfarin钠（CAS 129-06-6）市场规模（按类型、应用、区域范围和预测）

Warfarin林钠（CAS 129-06-6）市场规模及预测

2024 年华Warfarin钠 (CAS 129-06-6) 市场规模价值 1976.9 亿美元，预计到 2032 年将达到 2833.0 亿美元，2026 年至 2032 年的复合年增长率为 4.60%。

Warfarin钠用于预防血液凝固的日益增长的偏好，催生了医疗保健领域对该产品的需求，从而推动了全球市场的成长。本报告对全球Warfarin钠 (CAS 129-06-6) 市场进行了全面评估，全面分析了关键细分市场、趋势、市场驱动因素、限制因素、竞争格局以及影响市场的关键因素。

华法林钠 (CAS 129-06-6) 市场预计将以 4.60% 的复合年增长率增长，到 2032 年底达到 2833 亿美元

华法林钠的全球市场定义（CAS 129-06-6）

Warfarin钠是Warfarin的钠盐，具有抗凝血活性。 CAS 129-06-6 是化学文摘社为Warfarin林钠分配的唯一数字识别码。此药物常用于治疗血栓，例如深层静脉栓塞症和肺动脉栓塞，以及预防心房颤动、心臟瓣膜疾病或人工心臟瓣膜患者的中风。Warfarin钠有三种剂型：1 毫克锭剂、2.5 毫克锭剂和 5 毫克锭剂。

华法林钠通常是口服，但也会静脉注射。Warfarin钠可抑制维生素K和维生素K环氧化物还原酶，阻止维生素K环氧化物与其还原形式维生素KH2的循环转化。维生素KH2是维生素K依赖性蛋白质N端麸胺酸羧基化的辅酶。最常见的副作用是出血，较少见的副作用包括组织损伤部位和紫脚指综合症。

全球Warfarin钠（CAS 129-06-6）市场概览

因此，Warfarin钠用于预防血液凝固的日益增长的偏好，正在创造医疗保健领域对该产品的需求，从而推动全球市场的成长。然而，Warfarin钠的多种副作用，例如红色或棕色尿液、黑便或血便、严重头痛或胃痛、关节痛、呕吐和呕血，正在阻碍全球市场的成长。此外，过量摄取摄取Warfarin钠会导致严重血便和比正常情况下更严重的月经出血，这预计也会限制市场的成长。

目录

第 1 章。全球Warfarin钠（CAS 129-06-6）市场介绍

• 市场概览
• 研究范围
• 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

第四章Warfarin林钠（CAS 129-06-6）全球市场展望

• 概述
• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 波特五力模型
• 价值链分析

第五章全球Warfarin钠（CAS 129-06-6）市场类型

• 概述
• 1毫克片剂
• 2.5毫克片剂
• 5毫克片剂

第六章 全球Warfarin钠（CAS 129-06-6）市场应用

• 概述
• 医院药房
• 零售药局
• 网路药局

第七章 全球Warfarin钠（CAS 129-06-6）市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 其他的
  • 拉丁美洲
  • 中东和非洲

8. 全球Warfarin钠（CAS 129-06-6）市场的竞争格局

• 概述
• 各公司市场排名
• 重点发展策略

第九章 公司简介

• Qilu Pharma
• Sine Pharma
• Jialin Pharma
• Fuda Pharma
• Zhongjie Pharma
• Amneal Pharma
• TEVA
• Mylan
• Cipla

第十章 附录

• 相关调查

Warfarin Sodium (CAS 129-06-6) Market Size And Forecast

Warfarin Sodium (CAS 129-06-6) Market size was valued at USD 197.69 Billion in 2024 and is projected to reach USD 283.3 Billion by 2032, growing at a CAGR of 4.60% from 2026 to 2032.

The increasing preference for warfarin sodium for the prevention of blood clotting has created the demand for this product in healthcare, thereby driving the global market growth. The Global Warfarin Sodium (CAS 129-06-6) Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Warfarin Sodium (CAS 129-06-6) Market is estimated to grow at a CAGR of 4.60% & reach US$ 283.3 Bn by the end of 2032

Global Warfarin Sodium (CAS 129-06-6) Market Definition

Warfarin Sodium is the sodium salt form of warfarin, with anticoagulant activity. CAS 129-06-6 is a unique numerical identifier of warfarin sodium assigned by the Chemical Abstracts Service. It is commonly used to treat blood clots such as deep vein thrombosis and pulmonary embolism, and to prevent stroke in people who have atrial fibrillation, valvular heart disease, or artificial heart valves. Warfarin Sodium is categorized into three types: 1 mg/Tablet, 2.5 mg/Tablet, and 5 mg/Tablet.

It is generally taken by mouth, but can also be used by injection into a vein. Warfarin sodium inhibits vitamin K and vitamin K epoxide reductases, thereby obstructing the cyclic interconversion of vitamin K epoxide to its diminished form, vitamin KH2. Vitamin KH2 is a cofactor for the carboxylation of glutamate resting on the N-terminal regions of vitamin K-dependent proteins. The most common side effect is bleeding and less common side effects include areas of tissue damage and purple toes syndrome.

Global Warfarin Sodium (CAS 129-06-6) Market Overview

Thus, the increasing preference for warfarin sodium for the prevention of blood clotting has created the demand for this product in healthcare, thereby driving the global market growth. However, the several side effects of warfarin sodium such as red or brown urine, black or bloody stool, severe headache or stomach pain, joint pain, vomiting, and coughing up blood are hampering the global market growth. Overdose of warfarin sodium also leads to severe blooding or heavier than normal menstrual bleeding, which is also expected to restrict the market growth.

Global Warfarin Sodium (CAS 129-06-6) Market Segmentation Analysis

The Global Warfarin Sodium (CAS 129-06-6) Market Is Segmented On The Basis Of Type, Application, And Geography.

Warfarin Sodium (CAS 129-06-6) Market, By Type

1mg/Tablet

• 2.5mg/Tablet

5mg/Tablet

Based on Type, the market is segmented into 1mg/Tablet, 2.5mg/Tablet, and 5mg/Tablet. Warfarin, an anticoagulant works by preventing the formation of harmful blood clots. Although it does not dissolve the existing blood clots, it prevents them from growing larger and causing blockages in the blood vessels. It also has a common side effect of Bleeding. Hence it is always advised to consume Warfarin in small amounts. Hence 1mg/Tablets are consumed more and these factors are expected to boost demand for 1mg/Tablets and further propel market growth.

Warfarin Sodium (CAS 129-06-6) Market, By Application

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Based on Application, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital pharmacies usually stock a larger variety of medications, including more specialized and investigational medications, than would be feasible in the community setting. Pharmacists in hotels are more trained and equipped. Warfarin can interact with several medicines hence expert advice is always needed. These factors are expected to boost demand and further propel market growth.

Warfarin Sodium (CAS 129-06-6) Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of Geography, the Global Warfarin Sodium (CAS 129-06-6) Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The Europe market is said to be the Fastest Growing Market for Warfarin Sodium (CAS 129-06-6) because there is the highest awareness of deep vein thrombosis and pulmonary embolism and Warfarin is used to prevent stroke prevention, deep vein thrombosis, and pulmonary embolism. The Asia-Pacific place is predicted to develop because of a lack of awareness right now. With the increase in awareness the market will grow too.

Key Players

The "Global Warfarin Sodium (CAS 129-06-6) Market" study report will provide a valuable insight with an emphasis on the global market including some of the major players such as Qilu Pharma, Sine Pharma, Jialin Pharma, Fuda Pharma, Zhongjie Pharma, Amneal Pharma, TEVA, Mylan, and Cipla.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• Warfarin Sodium (CAS 129-06-6) Market Key Developments And Mergers
• In 2021, Arbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership.
• IN 2018, Qilu ranked top 10 of the Chinese Pharmaceutical Industry in 4 consecutive times.
• Cipla was awarded Company of the year 2021 buy the Business Standard.
• KEY COMPANIES PROFILED
• Qilu Pharma, Sine Pharma, Jialin Pharma, Fuda Pharma, Zhongjie Pharma, Amneal Pharma, TEVA, Mylan, and Cipla.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL WARFARIN SODIUM (CAS129-06-6) MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL WARFARIN SODIUM (CAS129-06-6) MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL WARFARIN SODIUM (CAS129-06-6) MARKET, BY TYPE

• 5.1 Overview
• 5.21mg/Tablet
• 5.3 2.5mg/Tablet
• 5.4 5mg/Tablet

6 GLOBAL WARFARIN SODIUM (CAS129-06-6) MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Hospital Pharmacies
• 6.3 Retail Pharmacies
• 6.4 Online Pharmacies

7 GLOBAL WARFARIN SODIUM (CAS129-06-6) MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL WARFARIN SODIUM (CAS129-06-6) MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Qilu Pharma
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Sine Pharma
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Jialin Pharma
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Fuda Pharma
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Zhongjie Pharma
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Amneal Pharma
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 TEVA
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Mylan
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Cipla
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments

10 Appendix

• 10.1 Related Research